This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Sequelae and prognosis

Authoring team

Sequelae will vary according to an individual's risk factors and the means of management employed.

Illustrative figures are presented for surgical and medical management:

  • laparoscopic salpingostomy - of 976 patients treated, 94% did not require any additional procedure.
  • systemic methotrexate - of 306 patients treated, 94% did not require any additional therapy.

The risk of ectopic pregnancy reoccurring is

  • around 10% in women with one previous ectopic pregnancy
  • at least 25% in women with two or more previous ectopic pregnancies (1)

According to population based cohort studies done on subsequent pregnancies after an ectopic pregnancy,

  • regardless of the treatment method (surgical or medical), 66% of women conceived after therapy with 90% reporting intrauterine pregnancy and 10% with recurrent ectopic pregnancy
  • around 62-70% intrauterine pregnancies and around 8% recurrent ectopic pregnancies were seen after methotrexate treatment (2)

Although maternal death from ectopic pregnancy has decreased, it is still the leading cause of death in the first trimester (2)

  • in UK there were 10 maternal deaths due to ectopic pregnancy between 2003-2005 (3)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.